Casodex® 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer: An overview of the efficacy, Tolerability and pharmacokinetics from Three Phase II Dose-ranging Studies

C. J. Tyrrell, L. Denis, D. Newling, M. Soloway, K. Channer, I. D. Cockshott

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Objectives: To evaluate the efficacy, tolerability, endocrinological effects and the pharmacokinetics of Casodex®, when given as monotherapy during daily dosing of 10-200 mg to patients with advanced prostate cancer. Methods: A total of 390 patients with advanced prostate cancer were treated for a minimum of 12 weeks with a daily monotherapy dose of Casodex. The doses ranged from 10 to 200 mg. Objective assessments of efficacy included: review of measurable metastases, prostate dimension, prostatic acid phosphatase and prostate-specific antigen (PSA) levels. Subjective assessments of efficacy included review of urological symptoms, performance status, bone scan and analgesic requirement. Pharmacokinetic samples were taken at various time points up to 3 months, and assayed using an achiral HPLC method. Results: Clear objective responses were observed, particularly at doses of 50 mg and above. Specifically, the median percentage decrease in PSA at 50 mg was 90.0%, and at 100 and 200 mg it was 93.4 and 94.8%, respectively. Up to 53% of symptomatic patients demonstrated a subjective response at 3 months. Casodex was well tolerated at all doses with no effect on haematological or cardiovascular parameters and no effect on renal function. The expected pharmacological effects of potent antiandrogen therapy, such as breast tenderness (58%), gynaecomastia (48%), and hot flushes (17%), were reported, but these incidences reflected the direct eliciting of these events. The intrinsic efficacy of Casodex was demonstrated despite increases of 60% in testosterone levels. However, this increase reached a plateau after 4-12 weeks of therapy, but the majority of values remained within the normal range. Casodex has a half-life of approximately 1 week, enabling once-daily dosing with no effect of age or renal impairment on its pharmacokinetics. Conclusion: Casodex has a favourable side effect profile compared with the known safety profiles of other antiandrogens and has demonstrated intrinsic efficacy. Casodex warrants further investigation as a monotherapy for the management of advanced prostate cancer.

Original languageEnglish
Pages (from-to)39-53
Number of pages15
JournalEuropean Urology
Volume33
Issue number1
DOIs
StatePublished - Jan 23 1998
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Pharmacokinetics
Androgen Antagonists
Prostate-Specific Antigen
Therapeutics
Kidney
bicalutamide
Half-Life
Analgesics
Testosterone
Prostate
Reference Values
Breast
High Pressure Liquid Chromatography
Pharmacology
Neoplasm Metastasis
Safety
Bone and Bones
Incidence

Keywords

  • Advanced prostate cancer
  • Casodex
  • Dose-ranging
  • Monotherapy
  • Pharmacokinetics

ASJC Scopus subject areas

  • Urology

Cite this

Casodex® 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer : An overview of the efficacy, Tolerability and pharmacokinetics from Three Phase II Dose-ranging Studies. / Tyrrell, C. J.; Denis, L.; Newling, D.; Soloway, M.; Channer, K.; Cockshott, I. D.

In: European Urology, Vol. 33, No. 1, 23.01.1998, p. 39-53.

Research output: Contribution to journalArticle

@article{1119f9e31b574cc59ce02e8cba344c56,
title = "Casodex{\circledR} 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer: An overview of the efficacy, Tolerability and pharmacokinetics from Three Phase II Dose-ranging Studies",
abstract = "Objectives: To evaluate the efficacy, tolerability, endocrinological effects and the pharmacokinetics of Casodex{\circledR}, when given as monotherapy during daily dosing of 10-200 mg to patients with advanced prostate cancer. Methods: A total of 390 patients with advanced prostate cancer were treated for a minimum of 12 weeks with a daily monotherapy dose of Casodex. The doses ranged from 10 to 200 mg. Objective assessments of efficacy included: review of measurable metastases, prostate dimension, prostatic acid phosphatase and prostate-specific antigen (PSA) levels. Subjective assessments of efficacy included review of urological symptoms, performance status, bone scan and analgesic requirement. Pharmacokinetic samples were taken at various time points up to 3 months, and assayed using an achiral HPLC method. Results: Clear objective responses were observed, particularly at doses of 50 mg and above. Specifically, the median percentage decrease in PSA at 50 mg was 90.0{\%}, and at 100 and 200 mg it was 93.4 and 94.8{\%}, respectively. Up to 53{\%} of symptomatic patients demonstrated a subjective response at 3 months. Casodex was well tolerated at all doses with no effect on haematological or cardiovascular parameters and no effect on renal function. The expected pharmacological effects of potent antiandrogen therapy, such as breast tenderness (58{\%}), gynaecomastia (48{\%}), and hot flushes (17{\%}), were reported, but these incidences reflected the direct eliciting of these events. The intrinsic efficacy of Casodex was demonstrated despite increases of 60{\%} in testosterone levels. However, this increase reached a plateau after 4-12 weeks of therapy, but the majority of values remained within the normal range. Casodex has a half-life of approximately 1 week, enabling once-daily dosing with no effect of age or renal impairment on its pharmacokinetics. Conclusion: Casodex has a favourable side effect profile compared with the known safety profiles of other antiandrogens and has demonstrated intrinsic efficacy. Casodex warrants further investigation as a monotherapy for the management of advanced prostate cancer.",
keywords = "Advanced prostate cancer, Casodex, Dose-ranging, Monotherapy, Pharmacokinetics",
author = "Tyrrell, {C. J.} and L. Denis and D. Newling and M. Soloway and K. Channer and Cockshott, {I. D.}",
year = "1998",
month = "1",
day = "23",
doi = "10.1159/000019526",
language = "English",
volume = "33",
pages = "39--53",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Casodex® 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer

T2 - An overview of the efficacy, Tolerability and pharmacokinetics from Three Phase II Dose-ranging Studies

AU - Tyrrell, C. J.

AU - Denis, L.

AU - Newling, D.

AU - Soloway, M.

AU - Channer, K.

AU - Cockshott, I. D.

PY - 1998/1/23

Y1 - 1998/1/23

N2 - Objectives: To evaluate the efficacy, tolerability, endocrinological effects and the pharmacokinetics of Casodex®, when given as monotherapy during daily dosing of 10-200 mg to patients with advanced prostate cancer. Methods: A total of 390 patients with advanced prostate cancer were treated for a minimum of 12 weeks with a daily monotherapy dose of Casodex. The doses ranged from 10 to 200 mg. Objective assessments of efficacy included: review of measurable metastases, prostate dimension, prostatic acid phosphatase and prostate-specific antigen (PSA) levels. Subjective assessments of efficacy included review of urological symptoms, performance status, bone scan and analgesic requirement. Pharmacokinetic samples were taken at various time points up to 3 months, and assayed using an achiral HPLC method. Results: Clear objective responses were observed, particularly at doses of 50 mg and above. Specifically, the median percentage decrease in PSA at 50 mg was 90.0%, and at 100 and 200 mg it was 93.4 and 94.8%, respectively. Up to 53% of symptomatic patients demonstrated a subjective response at 3 months. Casodex was well tolerated at all doses with no effect on haematological or cardiovascular parameters and no effect on renal function. The expected pharmacological effects of potent antiandrogen therapy, such as breast tenderness (58%), gynaecomastia (48%), and hot flushes (17%), were reported, but these incidences reflected the direct eliciting of these events. The intrinsic efficacy of Casodex was demonstrated despite increases of 60% in testosterone levels. However, this increase reached a plateau after 4-12 weeks of therapy, but the majority of values remained within the normal range. Casodex has a half-life of approximately 1 week, enabling once-daily dosing with no effect of age or renal impairment on its pharmacokinetics. Conclusion: Casodex has a favourable side effect profile compared with the known safety profiles of other antiandrogens and has demonstrated intrinsic efficacy. Casodex warrants further investigation as a monotherapy for the management of advanced prostate cancer.

AB - Objectives: To evaluate the efficacy, tolerability, endocrinological effects and the pharmacokinetics of Casodex®, when given as monotherapy during daily dosing of 10-200 mg to patients with advanced prostate cancer. Methods: A total of 390 patients with advanced prostate cancer were treated for a minimum of 12 weeks with a daily monotherapy dose of Casodex. The doses ranged from 10 to 200 mg. Objective assessments of efficacy included: review of measurable metastases, prostate dimension, prostatic acid phosphatase and prostate-specific antigen (PSA) levels. Subjective assessments of efficacy included review of urological symptoms, performance status, bone scan and analgesic requirement. Pharmacokinetic samples were taken at various time points up to 3 months, and assayed using an achiral HPLC method. Results: Clear objective responses were observed, particularly at doses of 50 mg and above. Specifically, the median percentage decrease in PSA at 50 mg was 90.0%, and at 100 and 200 mg it was 93.4 and 94.8%, respectively. Up to 53% of symptomatic patients demonstrated a subjective response at 3 months. Casodex was well tolerated at all doses with no effect on haematological or cardiovascular parameters and no effect on renal function. The expected pharmacological effects of potent antiandrogen therapy, such as breast tenderness (58%), gynaecomastia (48%), and hot flushes (17%), were reported, but these incidences reflected the direct eliciting of these events. The intrinsic efficacy of Casodex was demonstrated despite increases of 60% in testosterone levels. However, this increase reached a plateau after 4-12 weeks of therapy, but the majority of values remained within the normal range. Casodex has a half-life of approximately 1 week, enabling once-daily dosing with no effect of age or renal impairment on its pharmacokinetics. Conclusion: Casodex has a favourable side effect profile compared with the known safety profiles of other antiandrogens and has demonstrated intrinsic efficacy. Casodex warrants further investigation as a monotherapy for the management of advanced prostate cancer.

KW - Advanced prostate cancer

KW - Casodex

KW - Dose-ranging

KW - Monotherapy

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0031614610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031614610&partnerID=8YFLogxK

U2 - 10.1159/000019526

DO - 10.1159/000019526

M3 - Article

C2 - 9471040

AN - SCOPUS:0031614610

VL - 33

SP - 39

EP - 53

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 1

ER -